JP2017181518A - ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー - Google Patents
ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー Download PDFInfo
- Publication number
- JP2017181518A JP2017181518A JP2017111070A JP2017111070A JP2017181518A JP 2017181518 A JP2017181518 A JP 2017181518A JP 2017111070 A JP2017111070 A JP 2017111070A JP 2017111070 A JP2017111070 A JP 2017111070A JP 2017181518 A JP2017181518 A JP 2017181518A
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- tau
- injury
- brain
- gfap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000006378 damage Effects 0.000 title claims description 98
- 208000014674 injury Diseases 0.000 title claims description 73
- 208000027418 Wounds and injury Diseases 0.000 title claims description 65
- 108090000623 proteins and genes Proteins 0.000 title abstract description 85
- 102000004169 proteins and genes Human genes 0.000 title abstract description 84
- 238000003745 diagnosis Methods 0.000 title abstract description 10
- 230000001537 neural effect Effects 0.000 title description 18
- -1 autoantibody Proteins 0.000 title description 8
- 108091070501 miRNA Proteins 0.000 title description 7
- 239000000090 biomarker Substances 0.000 claims abstract description 237
- 238000000034 method Methods 0.000 claims abstract description 93
- 239000012472 biological sample Substances 0.000 claims abstract description 88
- 230000008569 process Effects 0.000 claims abstract description 28
- 230000000926 neurological effect Effects 0.000 claims description 54
- 210000002569 neuron Anatomy 0.000 claims description 34
- 230000008859 change Effects 0.000 claims description 11
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract description 107
- 230000009529 traumatic brain injury Effects 0.000 abstract description 106
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 abstract description 100
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 abstract description 100
- 210000002966 serum Anatomy 0.000 abstract description 69
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract description 47
- 238000001514 detection method Methods 0.000 abstract description 46
- 108700011259 MicroRNAs Proteins 0.000 abstract description 42
- 210000004556 brain Anatomy 0.000 abstract description 42
- 210000002381 plasma Anatomy 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 208000029028 brain injury Diseases 0.000 abstract description 18
- 208000006011 Stroke Diseases 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 12
- 230000015556 catabolic process Effects 0.000 abstract description 8
- 239000002679 microRNA Substances 0.000 abstract description 8
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 208000018737 Parkinson disease Diseases 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 4
- 208000037890 multiple organ injury Diseases 0.000 abstract description 2
- 230000002797 proteolythic effect Effects 0.000 abstract description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 abstract 2
- 208000017004 dementia pugilistica Diseases 0.000 abstract 2
- 208000000532 Chronic Brain Injury Diseases 0.000 abstract 1
- 231100000878 neurological injury Toxicity 0.000 abstract 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 99
- 235000018102 proteins Nutrition 0.000 description 79
- 241000282414 Homo sapiens Species 0.000 description 67
- 239000000523 sample Substances 0.000 description 59
- 102000013498 tau Proteins Human genes 0.000 description 57
- 108010026424 tau Proteins Proteins 0.000 description 57
- 102000007590 Calpain Human genes 0.000 description 49
- 108010032088 Calpain Proteins 0.000 description 49
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 44
- 241000700159 Rattus Species 0.000 description 40
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 39
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 37
- 239000003814 drug Substances 0.000 description 35
- 102000011727 Caspases Human genes 0.000 description 32
- 108010076667 Caspases Proteins 0.000 description 32
- 238000011282 treatment Methods 0.000 description 32
- 239000007857 degradation product Substances 0.000 description 31
- 102000039446 nucleic acids Human genes 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 31
- 150000007523 nucleic acids Chemical class 0.000 description 31
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 238000003776 cleavage reaction Methods 0.000 description 28
- 230000007017 scission Effects 0.000 description 28
- 238000003556 assay Methods 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 26
- 102000053602 DNA Human genes 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 230000001404 mediated effect Effects 0.000 description 22
- 229940124597 therapeutic agent Drugs 0.000 description 22
- 238000001262 western blot Methods 0.000 description 22
- 239000006166 lysate Substances 0.000 description 21
- 239000000758 substrate Substances 0.000 description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 20
- 239000003550 marker Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 14
- 210000004899 c-terminal region Anatomy 0.000 description 14
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 14
- 101710157175 Spectrin alpha chain, non-erythrocytic 1 Proteins 0.000 description 13
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 108090000397 Caspase 3 Proteins 0.000 description 12
- 102000003952 Caspase 3 Human genes 0.000 description 12
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000003961 neuronal insult Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 102000003900 Calpain-2 Human genes 0.000 description 11
- 108090000232 Calpain-2 Proteins 0.000 description 11
- 102000057063 human MAPT Human genes 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 239000002033 PVDF binder Substances 0.000 description 10
- 210000001124 body fluid Anatomy 0.000 description 10
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 10
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 10
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 10
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 9
- 102000003895 Calpain-1 Human genes 0.000 description 9
- 108090000236 Calpain-1 Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 101100480719 Rattus norvegicus Mapt gene Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000001320 hippocampus Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 8
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 8
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 8
- 102000047918 Myelin Basic Human genes 0.000 description 8
- 101710107068 Myelin basic protein Proteins 0.000 description 8
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 8
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 210000003296 saliva Anatomy 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- PMEQLUMDXFJNRY-SFTDATJTSA-N 2-(2-methoxyethoxy)ethyl n-[(2s)-1-[[(2s)-4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCCOCCOC)C(=O)C(=O)NC1CC1)C1=CC=CC=C1 PMEQLUMDXFJNRY-SFTDATJTSA-N 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 7
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 229960000485 methotrexate Drugs 0.000 description 7
- 230000003551 muscarinic effect Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108091023037 Aptamer Proteins 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 description 5
- 108090000371 Esterases Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 5
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 5
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 5
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 102000034337 acetylcholine receptors Human genes 0.000 description 5
- 230000006931 brain damage Effects 0.000 description 5
- 231100000874 brain damage Toxicity 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 108010079785 calpain inhibitors Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003656 tris buffered saline Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 229940121926 Calpain inhibitor Drugs 0.000 description 4
- 102100035037 Calpastatin Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000888419 Homo sapiens Glial fibrillary acidic protein Proteins 0.000 description 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 102000008880 Peptidase C12, ubiquitin carboxyl-terminal hydrolases Human genes 0.000 description 4
- 108050000823 Peptidase C12, ubiquitin carboxyl-terminal hydrolases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 230000004570 RNA-binding Effects 0.000 description 4
- 102000013008 Semaphorin-3A Human genes 0.000 description 4
- 108010090319 Semaphorin-3A Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 108010044208 calpastatin Proteins 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 102000051520 human GFAP Human genes 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 4
- 208000007333 Brain Concussion Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 229940123169 Caspase inhibitor Drugs 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 102100021487 Protein S100-B Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000008816 organ damage Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 description 2
- 102100040458 2',3'-cyclic-nucleotide 3'-phosphodiesterase Human genes 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 102100024075 Alpha-internexin Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- 102100023057 Neurofilament light polypeptide Human genes 0.000 description 2
- 102100037591 Neuroserpin Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000005890 Spectrin Human genes 0.000 description 2
- 108010019965 Spectrin Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 2
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
- 108010011385 alpha-internexin Proteins 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229940127243 cholinergic drug Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 210000005257 cortical tissue Anatomy 0.000 description 2
- 238000007428 craniotomy Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960003776 glatiramer acetate Drugs 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 102000057986 human UCHL1 Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005049 internexin Anatomy 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108091043249 miR-135-1 stem-loop Proteins 0.000 description 2
- 108091064876 miR-135-2 stem-loop Proteins 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 108010080874 neuroserpin Proteins 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WEBMRZODPLSRKR-MLBSPLJJSA-N (e)-n-methoxy-1-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)methanimine;hydrochloride Chemical compound Cl.CO\N=C\C1=CCCN(C)C1 WEBMRZODPLSRKR-MLBSPLJJSA-N 0.000 description 1
- MMUQVFDMUDOFSH-ONNFQVAWSA-N 1-azabicyclo[2.2.2]octan-3-yl (e)-2-hydroxy-5-iodo-2-phenylpent-4-enoate Chemical compound C1N(CC2)CCC2C1OC(=O)C(C\C=C\I)(O)C1=CC=CC=C1 MMUQVFDMUDOFSH-ONNFQVAWSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000013883 Blast injury Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150060249 CHRM3 gene Proteins 0.000 description 1
- 229940122642 Calcium channel agonist Drugs 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102100025172 Calpain-1 catalytic subunit Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 101150073075 Chrm1 gene Proteins 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 102100024426 Dihydropyrimidinase-related protein 2 Human genes 0.000 description 1
- 108050002467 Dihydropyrimidinase-related protein 2 Proteins 0.000 description 1
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102100028410 Endophilin-A1 Human genes 0.000 description 1
- 101710197301 Endophilin-A1 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000034575 Glutamate transporters Human genes 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- FMPNFDSPHNUFOS-HQEQRHKESA-N Himbacine Natural products C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-HQEQRHKESA-N 0.000 description 1
- 101000934069 Homo sapiens Calpain-1 catalytic subunit Proteins 0.000 description 1
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
- 101000969594 Homo sapiens Modulator of apoptosis 1 Proteins 0.000 description 1
- 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 description 1
- 101000979321 Homo sapiens Neurofilament medium polypeptide Proteins 0.000 description 1
- 101000574396 Homo sapiens Protein phosphatase 1K, mitochondrial Proteins 0.000 description 1
- 101000673946 Homo sapiens Synaptotagmin-like protein 1 Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 108091028080 MiR-132 Proteins 0.000 description 1
- 108090001040 Microtubule-associated protein 1B Proteins 0.000 description 1
- 102000004866 Microtubule-associated protein 1B Human genes 0.000 description 1
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
- 108091027966 Mir-137 Proteins 0.000 description 1
- 108091028049 Mir-221 microRNA Proteins 0.000 description 1
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 description 1
- 102100021440 Modulator of apoptosis 1 Human genes 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010008409 Muscarinic M5 Receptor Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- FMPNFDSPHNUFOS-UHFFFAOYSA-N N-Methyl-himandravin Natural products C12C(C)OC(=O)C2CC2CCCCC2C1C=CC1CCCC(C)N1C FMPNFDSPHNUFOS-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 1
- 101710159895 Neurofilament heavy polypeptide Proteins 0.000 description 1
- 102100023055 Neurofilament medium polypeptide Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101100131116 Oryza sativa subsp. japonica MPK3 gene Proteins 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 102100028465 Peripherin Human genes 0.000 description 1
- 108010003081 Peripherins Proteins 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920009405 Polyvinylidenefluoride (PVDF) Film Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710122255 Protein S100-B Proteins 0.000 description 1
- 102100025799 Protein phosphatase 1K, mitochondrial Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000746366 Rattus norvegicus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 101100456045 Schizosaccharomyces pombe (strain 972 / ATCC 24843) map3 gene Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000017299 Synapsin-1 Human genes 0.000 description 1
- 108050005241 Synapsin-1 Proteins 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 108010055170 Synaptotagmin I Proteins 0.000 description 1
- 102100036417 Synaptotagmin-1 Human genes 0.000 description 1
- 102100040541 Synaptotagmin-like protein 1 Human genes 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
- 101100107916 Xenopus laevis chrm4 gene Proteins 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960003216 aceclidine Drugs 0.000 description 1
- WRJPSSPFHGNBMG-UHFFFAOYSA-N acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
- 229960000910 bethanechol Drugs 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000000801 calcium channel stimulating agent Substances 0.000 description 1
- ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- WUTYZMFRCNBCHQ-PSASIEDQSA-N cevimeline Chemical compound C1S[C@H](C)O[C@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-PSASIEDQSA-N 0.000 description 1
- 229960001314 cevimeline Drugs 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- FMPNFDSPHNUFOS-LPJDIUFZSA-N himbacine Chemical compound C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-LPJDIUFZSA-N 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 108091055434 miR-124a stem-loop Proteins 0.000 description 1
- 108091082871 miR-124a-2 stem-loop Proteins 0.000 description 1
- 108091050112 miR-124a-4 stem-loop Proteins 0.000 description 1
- 108091054623 miR-124a-5 stem-loop Proteins 0.000 description 1
- 108091024680 miR-124a-6 stem-loop Proteins 0.000 description 1
- 108091024609 miR-124b stem-loop Proteins 0.000 description 1
- 108091081188 miR-124b-1 stem-loop Proteins 0.000 description 1
- 108091060300 miR-124b-2 stem-loop Proteins 0.000 description 1
- 108091044988 miR-125a stem-loop Proteins 0.000 description 1
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 description 1
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 description 1
- 108091091360 miR-125b stem-loop Proteins 0.000 description 1
- 108091070946 miR-128 stem-loop Proteins 0.000 description 1
- 108091029379 miR-139 stem-loop Proteins 0.000 description 1
- 108091033783 miR-153 stem-loop Proteins 0.000 description 1
- 108091029500 miR-183 stem-loop Proteins 0.000 description 1
- 108091058965 miR-218a stem-loop Proteins 0.000 description 1
- 108091063841 miR-219 stem-loop Proteins 0.000 description 1
- 108091080321 miR-222 stem-loop Proteins 0.000 description 1
- 108091074487 miR-34 stem-loop Proteins 0.000 description 1
- 108091092493 miR-34-1 stem-loop Proteins 0.000 description 1
- 108091059780 miR-34-2 stem-loop Proteins 0.000 description 1
- 108091047084 miR-9 stem-loop Proteins 0.000 description 1
- 108091038507 miR-92b stem-loop Proteins 0.000 description 1
- 108091081014 miR-92b-1 stem-loop Proteins 0.000 description 1
- 108091032846 miR-92b-2 stem loop Proteins 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000005047 peripherin Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- VVLMSCJCXMBGDI-UHFFFAOYSA-M trimethyl-[4-(2-oxopyrrolidin-1-yl)but-2-ynyl]azanium;iodide Chemical compound [I-].C[N+](C)(C)CC#CCN1CCCC1=O VVLMSCJCXMBGDI-UHFFFAOYSA-M 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 description 1
- 229950006755 xanomeline Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
【解決手段】工程および材料は、全血、血清、血漿またはCSFのような生物試料中で検出または測定されるバイオマーカーを含む。上記バイオマーカーは、タウおよびGFAPタンパク質、これらのタンパク質分解産物、脳に特異的なまたは脳に多く存在するマイクロRNA、ならびに脳に特異的なまたは脳に多く存在するタンパク質に対する自己抗体を含む。工程および材料は、急性、亜急性または慢性脳損傷の有無を検出すること、および脳損傷の転帰を予測することに使用できる。
【選択図】図34
Description
本願は、2009年9月14日に出願された米国特許仮出願第61/242,123号、2010年6月14日に出願された同第61/354,504号、2010年6月17日に出願された同第61/355,779号および2010年9月3日に出願された同第61/380,158号に対する優先権を主張するものであり、上記各明細書はその内容全体が本明細書に組み込まれる。
本発明の実施の際に使用する試薬の具体例としては、炭酸水素ナトリウム(Sigma カタログ番号:C−3041)、ブロッキング緩衝液(Startingblock T20−TBS)(Pierce カタログ番号:37543)、Tween20を含むトリス緩衝生理食塩水 (TBST;Sigma カタログ番号:T−9039)、リン酸緩衝生理食塩水(PBS;Sigma カタログ番号:P−3813);Tween20(Sigma カタログ番号:P5927);Ultra TMB ELISA(Pierce カタログ番号:34028);およびNunc maxisorp ELISAプレート(Fisher)が挙げられる。モノクローナルおよびポリクローナルのGFAPおよびUCHL1抗体は、自社製またはSanta Cruz Biotechnology、Santa Cruz、CAから入手したものである。αIIスペクトリン、GFAPおよび分解産物、ならびにMAP2、MBP、ニューロファシン、IgGおよびIgMに対する抗体は、Santa Cruz Biotechnology、Santa Cruz、CAから入手可能である。
抗バイオマーカー特異的ウサギポリクローナル抗体およびモノクローナル抗体ならびに抗原を研究室で作製するか、または市販のものを購入する。標的バイオマーカーを検出するための抗体の反応特異性を判定するために、既知量の単離されたまたは部分的に単離されたバイオマーカーを解析するか、または組織パネルをウエスタンブロットによりプローブする。ELISAプレートに結合させた組換えバイオマーカータンパク質による間接ELISAを用いて、アッセイで使用する抗体の最適濃度を決定する。マイクロプレートをウサギポリクローナル抗ヒトバイオマーカー抗体でコーティングする。最大シグナルのウサギ抗ヒトバイオマーカー抗体濃度を決定した後、間接ELISAの検出下限を各抗体に関して決定する。適当な希釈試料を、ウサギポリクローナル抗ヒトバイオマーカー抗体と2時間インキュベートし、次いで洗浄する。次いで、ビオチン標識モノクローナル抗ヒトバイオマーカー抗体を加え、捕捉されたバイオマーカーとインキュベートする。十分に洗浄した後、ストレプトアビジン西洋ワサビペルオキシダーゼコンジュゲートを加える。1時間のインキュベーションおよび最後の洗浄段階の後、残ったコンジュゲートを過酸化水素テトラメチルベンザジンの基質と反応させる。酸性溶液の添加により反応を停止させ、得られた黄色反応産物の吸光度を450メートルで測定する。吸光度はバイオマーカーの濃度に比例する。較正物質試料を用いて、吸光度値をバイオマーカー濃度の関数としてプロットすることにより標準曲線を作成し、この標準曲線を用いて未知試料の濃度を決定する。
制御式皮質衝撃(CCI)装置を用いて、既に記載されている通りにラットでTBIモデルを作製する(Pikeら,1998)。成体雄(280〜300g)Sprague−Dawleyラット(Harlan:Indianapolis、IN)を、1:1O2/N2Oのキャリヤガス中4%のイソフルランで麻酔し(4分)、同じキャリヤガス中2.5%のイソフルランで維持する。中核体温を直腸内サーミスタプローブにより継続的にモニターし、ラットの下に調節可能な温度制御式加温パッドを敷いて37±1℃に維持する。ラットを腹臥位で定位フレームに載せ、耳棒および切歯棒で固定する。正中頭蓋切開および軟組織反転を行った後、ブレグマとラムダの中間部分、中央縫合のすぐ横で片側(衝撃部位と同側)開頭(直径7mm)を行う。皮質を覆う硬膜はそのままにしておく。直径5mmのアルミニウム製インパクタ先端部(空気圧シリンダー内に収納されている)を用いて、圧縮1.6mmおよび休止時間150ms、3.5m/秒の速度で右側(同側)皮質に衝撃を与えて脳外傷を生じさせる。偽損傷コントロール個体には同じ外科処置を行うが、衝撃損傷は与えない。適切な損傷前および損傷後を行って、Florida大学の動物管理使用委員会(Institutional Animal Care and Use Committee)記載のガイドラインおよび実験動物の管理と使用に関する指針(Guide for the Care and Use of Laboratory Animals)で詳述されている米国国立衛生研究所ガイドラインを確実に遵守する。さらに、動物および動物実験に関連した動物福祉法(Animal Welfare Act)ならびにその他の連邦の制定法および規制に従って、また「Guide for the Care and Use of Laboratory Animals,NRC Publication,1996年版」に記載されている原則に忠実に従って研究を行う。
イソフルラン麻酔(導入チャンバを介した5%イソフルラン、次いでノーズコーンを介した2%イソフルラン)の下で温置し、正中頸部切開によりラットの右側総頸動脈(CCA)を外頸動脈および内頸動脈(ECAおよびICA)分岐レベルで露出させる。ICAを吻側に翼口蓋部の分岐までたどり、ECAを結紮して、その舌部および上顎部の分岐を切る。次いで、ECA断端の切開部分から3−0ナイロン縫合糸をICAに挿入し(血管壁を通して縫合糸の進路を視覚的に監視する)、前大脳動脈の狭窄部で詰まり中大脳動脈の起点を塞ぐまで、頸動脈管内を頸動脈分岐から約20mm進める。次いで皮膚の切開を閉じ、血管内の縫合糸を所定の位置で30分または2時間放置する。ラットを短時間、再び麻酔した後、縫合糸を引き抜いて再灌流させる。偽MCAO手術では、同じ手順に従うが、糸は内外頸動脈分岐から10mmだけ進め、ラットを屠殺するまで所定の位置に放置する。すべての外科的処置の間、保温毛布(Harvard Apparatus、Holliston、MA、U.S.A.)でマウスを37±1℃に維持した。各実験の終わりに、ラット脳が剖検時に、くも膜下出血の病理学的証拠を示した場合、それを実験から除外することに留意することが重要である。適切な損傷前および損傷後の管理を行って、動物の管理と使用のガイドラインをすべて確実に遵守する。
損傷後の適当な時点(2、6、24時間および2、3、5日)でマウスを麻酔し、断頭により直ちに屠殺する。脳を素早く取り出し、氷冷PBSで洗浄して二等分する。右半球(衝撃部位周辺の大脳皮質および海馬)を素早く解剖し、氷冷PBSで洗浄し、液体窒素で急速凍結させ、使用するまで−80℃で保管する。免疫組織化学用に、脳を乾燥氷スラリーで急速に凍結させ、SUPERFROST PLUS GOLD(登録商標)(Fisher Scientific)スライド上にクリオスタットで切片(20μm)を作製し、次いで使用するまで−80℃で保管する。左半球では、右側と同じ組織を採取した。ウエスタンブロット解析用に、脳試料を乾燥氷上で小型の乳鉢と乳棒のセットを用いて微粉末に粉砕する。次いで、粉砕した脳組織粉末を、50mMトリス(pH7.4)、5mM EDTA、1%(v/v)TritonX−100、1mM DTT、1×プロテアーゼインヒビターカクテル(Roche Biochemicals)の緩衝剤中、4℃で90分間、溶解させた。次いで、脳ライセートを4℃で5分間、15,000×gで遠心分離して清澄化し、不溶性の残骸を除去して、急速凍結させ、使用するまで−80℃で保管する。
実施例3に記載のラットでのCCIの後、実施例5の通りにCSFを調製する。抗GFAP抗体を用いたウエスタンブロット法により、CCI損傷後に経時的なGFAPの増加が明らかになっている(図1A、1B)。同様に、GFAPのレベルがCCI後に経時的に増加し、損傷後14日目に統計的に有意な最大レベルとなる(図1C)。ラット同側皮質におけるGFAPおよびGBDPのレベルも測定し、偽(1つまたは複数)処置個体に比べて増加したレベルが示される(図2)。これらのデータは、重度TBIと同様の、CCI後のCSFおよび神経組織におけるGFAPおよびGBDPの増加を示している。
調査には、重度外傷性脳損傷を有する46例のヒト対象が含まれていた。各対象は、年齢が19歳以上、GCSが8以下であり、かつ日常的な治療の一部として脳室フィステル形成術および神経モニタリングが必要であることを特徴とする。詳細にはCSFコントロールと同義であるコントロール群Aには、同様に19歳以上でかつ損傷を有さない10人が含まれていた。水頭症または髄膜炎の治療に関連した日常的な外科的処置またはCSF入手のための脊椎麻酔の際に試料を採取する。正常コントロールと同義として表されるコントロール群Bは、それぞれ18歳以上でかつ脳損傷を伴わない複数の損傷を経験している合計64人であった。調査の人口動態に関するさらなる詳細を表9に記載する。
重度TBI後、対象の血液中でニューロンタンパク質に対する自己抗体が産生され、で検出可能となる。ヒトTBI対象から死後に脳ライセートを入手し、20mMトリス−HCl、pH7.4、150mM NaCl、5mM EDTA、5mM EGTA、1%TritonX−100、1mM NaF、1mM Na3VO4およびプロテアーゼインヒビターカクテルタブレット(Roche、Indianapolis、IN)を含有する溶解緩衝液で可溶化する。SDS−PAGEによりライセートを分離し、次いで全タンパク質に関して染色し(図16A)、プロービングのためにポリフッ化ビニリデン(PVDF)膜(Bio−Rad Laboratories)上に転写する。ヒトコントロールドナーから採取(B)またはTBI10日後にヒトから採取(C)した血清を用いてブロットをプローブし、抗IgG/IgMを用いて自己抗体を検出する。TBI後の対象由来の血清では、血清自己抗体の存在を示す強いバンドが観察される。
TBI後の様々な時点でヒト対象から血清試料を採取する。表10は、3つの異なるTBI相:急性+亜急性相(損傷〜10日目);重度TBI亜急性相(1日目〜30日目);および重度TBI慢性相(TBI後1ヶ月超)で試料を得た患者数を示す。
自己抗体の存在と生存率との相関を解析するために、TBIと診断されたヒト対象の調査をさらに行う。重度(GCIスコアが3〜5)または軽度(GCIスコアが6〜15)TBIを有する20例のヒト対象から血清試料を採取する。表11は、調査対象の特徴を示す。
臓器または脳損傷後にタンパク質がCSFおよび血漿区画に侵入するのと同様に、RNAおよびDNAも侵入する。アポトーシスまたは壊死を起こしている細胞は、血液またはCSF中に核酸バイオマーカーを放出する(図34)。損傷の重症度および部位は、細胞タイプに特異的なRNA量を定量化する適当なリアルタイムPCRアッセイにより特定できる。神経特異的RNAの例としては、βIIIチューブリン、UCHL1、GFAPおよびシナプトフィジンが挙げられる。
TBIの1日後のヒト血清において、ヒトのTBIに関連したmiRNAの存在を検出する。血清を採取し、3000×gで15分間遠心分離し0.2マイクロメートルフィルターを通過させて無細胞とし、全RNAの調製に使用する。全RNA(5μg)を、YM−100 Microcon遠視分離フィルター(Millipore)を用いてサイズ分画する(b300ヌクレオチド)。回収した低分子RNA(b300nt)を、ポリ(A)ポリメラーゼを用いてポリ(A)テールで3’延長する。後の蛍光色素染色のために、オリゴヌクレオチタグをポリ(A)テールに連結する。低分子RNAを一晩、マイクロ循環ポンプを用いてμParafloマイクロ流体チップ上でハイブリダイズさせる(Atactic Technologies)。チップ上の各検出プローブは、標的ヒトmiRNA配列に相補的な化学修飾したヌクレオチドコードセグメントからなる。
Leon,SA et al (1977) Patients Cancer Research 37,646
Muller,H.M.et al (2003) Expert Rev Mol.Diagn. 3,443
Silva,JM et al(1999) Cancer Research,59,3251
Lo,YM et al (1997) Lancet
Menke,TM and Warnecke,JM(2004) Ann NY Acad.Sci 1022,185−189.
Hasselmann,D.O.et al(2001) Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin.Chem.47:1488−1489.
Circulating Nucleic acids in plasma and Serum(CNAPS)III and serum proteomics.Ann NY Acad Sci 1022(Eds.D.S.B.Hoon,B.Taback).
Tan E.M.et al.1966 Deoxyribonucleic acid(DNA)and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J.Clin.Invest.45:1732−1740.
Rainer,TH et al(2003) Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem.49:562−560.
Hmaouim K.,Butt,A.,Powrie,J.,and Swaminathan,R.(2004) Real−time Quantitative PCR Measurement of Circulatory Rhodopsin mRNA in Healthy Subjects and Patients with Diab etic Retinopathy.In Circulating Nucleic acids in plasma and Serum(CNAPS)III and serum proteomics.Ann NY Acad Sci 1022(Eds.D.S.B.Hoon,B.Taback).Pp 152−156.
Rainer,TH et al (2004) Effects of filtration on glyceraldehydes −3−phosphate dehydrogenase mRNA in the plasma of trauma patients and healthy individuals. Clin.Chem.50:206−208.
Terryberry JW,Thor G,Peter JB.(1998)Autoantibodies in neurodegenerative diseases:antigen−specific frequencies and intrathecal analysis.Neurobiol Aging 19:205−216.
Terryberry JW,Shoenfeld Y,Peter JB.(1998)Clinical utility of autoantibodies in Guillain−Barre syndrome and its variants.Clin Rev Allergy Immunol 16:265−273.
Dambinova SA,Khounteev GA,Izykenova GA,Zavolokov IG,Ilyukhina AY,Skoromets AA.(2003)Blood test detecting autoantibodies to N−methyl−D−aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke.Clin Chem 49:1752−1762.
Dambinova SA,Izykenova GA,Burov SV,Grigorenko EV,Gromov SA.(1997)The presence of autoantibodies to N−terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy.J Neurol Sci 152:93−97.
Goryunova AV,Bazarnaya NA,Sorokina EG,et al.(2007)Glutamate receptor autoantibody concentrations in children with chronic post−traumatic headache.Neurosci Behav Physiol 37:761−764.
ADAMS,J.H.,GRAHAM,D.I.,and JENNETT,B.(2000).The neuropathology of the vegetative state after an acute brain insult.Brain.123,1327−1338.
ARNAUD LT,MYEKU N,FIGUEIREDO−PEREIRA ME.(2009)Proteasome−caspase−cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells.J Neurochem.2009 110(1):328−42.
AVILA,J.,PEREZ,M.,LUCAS,J.J.,GOMEZ−RAMOS,A.,MARIA,I.S.,MORENO,F.,SMITH,M.,PERRY,G.,and HERNANDEZ,F.(2004).Assembly in vitro of tau protein and its implications in Alzheimer’s disease.Curr Alzheimer Res.1,97−101.
BARTUS,R.T.(1997).The calpain hypothesis of neurodegeneration:evidence for a common cytotoxic pathway.The Neuroscientist.3,314−327.
BEER,R.,FRANZ,G.,SRINIVASAN,A.,HAYES,R.L.,PIKE,B.R.,NEWCOMB,J.K.,ZHAO,X.,SCHMUTZHARD,E.,POEWE,W.,and KAMPFL,A.(2000).Temporal profile and cell subtype distribution of activated caspase−3 following experimental traumatic brain injury.Neurochem.75,1264−1273.
BINDER,L.I.,FRANKFURTER,A.,and REBHUN,L.I.(1985).The distribution of tau in the mammalian central nervous system.J.Cell Biol.101,1371−1378.
BITSCH,A.,HORN,C.,KEMMLING,Y.,SEIPELT,M.,HELLENBRND,U.,STIEFEL,M.,CIESIELCZYK,B.,CEPEK,L.,BAHN,E.,RATZKA,P.,PRANGE,H.,and OTTO,M.(2002).Serum tau protein level as a marker of axonal damage in acute ischemic stroke.Eur.Neurol.47,45−51.
BRAMLETT,H.M.,and DIETRICH,W.D.(2002).Quantitative structural changes in white and gray matter 1 year following traumatic brain injury in rats.Acta Neuropathol.(Berl).103,607−614.
BUKI,A.,OKONKWO,D.O.,WANG K.K.W.,and POVLISHOCK,J.T.(2000)Cytochrome c release and caspase activation in traumatic axonal injury.J.Neurosci.20,2825−2834.
BUKI,A.,SIMAN,R.,TROJANOWSKI,J.Q.,and POVLISHOCK,J.T.(1999).The role of calpain−mediated spectrin proteolysis in traumatically induced axonal injury.J.Neuropathol.Exp.Neurol.58,365−375.
BARTUS,R.T.(1997).The calpain hypothesis of neurodegeneration:evidence for a common cytotoxic pathway.The Neuroscientist.3,314−327.
CANU, N., DUS, L., BARBATO, C., CIOTTI, M.T., BRANCOLINI, C., RINALDI A.M., NOVAK, M., CATTANEO, A., BRADBURY A., and CALISSANO, P. (1998). Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J. Neurosci. 8, 7061−7074.
CHRISTMAN,C.W.,GRADY,M.S.,WALKER,S.A.,HOLLOWAY,K.L.,and POVLISHOCK,J.T.(1994).Ultrastructural studies of diffuse axonal injury in humans.J.Neurotrauma.11,173−186.
CHUNG,C.W.,SONG,Y.H.,KIM,I.K.,YOON,W.J.,RYE,B.R.,JO,D.G.,WOO,H.N.,KWON,Y.K.,KIM,H.H.,GWAG,B.J.,MOOK−JUNG,I.H.,and JUNG,Y.K.(2001).Proapoptotic effects of tau cleavage product generated by caspase−3.Neurobiol.Dis.8,162−172.
CLARK,R.S.,KOCHANEK,P.M.,WATKINS,S.C.,CHEN,M.,DIXON,C.E.,SEIDBERG,N.A.,MELICK,J.,LOEFFERT,J.E.,NATHANIEL,P.D.,JIN,K.L.,and GRAHAM,S.H.(2000).Caspase−3 mediated neuronal death after traumatic brain injury in rats.J.Neurochem. 74,740−753.
DELOBEL P,LEROY O,HAMDANE M,SAMBO AV,DELACOURTE A,BUEE L.(2005)Proteasome inhibition and Tau proteolysis: an unexpected regulation.FEBS Lett.579,1−5.
DIXON,C.E.,CLIFTON,G.L.,LIGHTHALL J.W.,YAGHMAI,A.A.,and HAYES,R.L.(1991).A controlled cortical impact model of traumatic brain injury in the rat.J.Neurosci. 39,253−262.
DRUBIN,D.G.,and KIRSCHNER,M.W.(1986).Tau protein function in living cells.J.Cell Biol.103,2739−2746.
FRANZ,G.,BEER,R.,KAMPFL,A.,ENGELHARDT,K.,SCHMUTZHARD,E.,ULMER,H.,and DEISENHAMMER,F.(1995).Amyloid beta 1−42 and tau in cerebrospinal fluid after severe traumatic brain injury.Neurology.60,1457−1461.
GABBITA SP,SCHEFF SW,MENARD RM,ROBERTS K,FUGACCIA I,ZEMLAN FP.(2005)Cleaved−tau:a biomarker of neuronal damage after traumatic brain injury.J Neurotrauma.22,83−94.
GAMBLIN TC,CHEN F,ZAMBRANO A,ABRAHA A,LAGALWAR S,GUILLOZET AL,LU M,FU Y,GARCIA−SIERRA F,LAPOINTE N,MILLER R,BERRY RW,BINDER LI,CRYNS VL.Caspase cleavage of tau,linking amyloid and neurofibrillary tangles in Alzheimer’s disease.Proc Natl Acad Sci USA 100,10032−10037.
GARCIA−SIERRA F,MONDRAGON−RODRIGUEZ S,BASURTO−ISLAS G.(2008).Truncation of tau protein and its pathological significance in Alzheimer’s disease.J Alzheimers Dis.14,401−9.
GALE,S.D.,JOHNSON,S.C.,BIGLER,E.D.,and BLATTER,D.D.(1995).Nonspecific white matter degeneration following traumatic brain injury.J.Int.Neuropsychol.Soc.1,17−28.
GARCIA,M.L.,and CLEVELAND,D.W.(2001).Going new places using an old MAP:tau,microtubules and human neurodegenerative diseases.Curr.Opin.Cell Biol.13,41−48.
GUILLOZET−BONGAARTS AL,GARCIA−SIERRA F,REYNOLDS MR,HOROWITZ PM,FU Y,WANG T,CAHILL ME,BIGIO EH,BERRY RW,BINDER LI.(2005)Tau truncation during neurofibrillary tangle evolution in Alzheimer’s disease.Neurobiol Aging.26,1015−1022.
HIGUCHI,M.,LEE,V.M.,and TROJANOWSKI,J.Q.(2002).Tau and axonopathy in neurodegenerative disorders.Neuromolecular Med.2,131−150.
JOHNSON,G.V.,JOPE,R.S.,and BINDER,L.I.(1989).Proteolysis of tau by calpain.Biochem.Biophys.Res.Commun.163,1505−1511.
KAMPFL,A.,POSMANTUR,R.M.,ZHAO,X.,SCHMUTZHARD,E.,CLIFTON,G.L.,and HAYES R.L.(1997).Mechanisms of calpain proteolysis following traumatic brain injury:implications for pathology and therapy:a review and update.J.Neurotrauma 14,121−134.
KIRALY M,KIRALY SJ.(2007)Traumatic brain injury and delayed sequelae:a review−−traumatic brain injury and mild traumatic brain injury(concussion)are precursors to later−onset brain disorders,including early−onset dementia.ScientificWorldJournal.2007 Nov 12;7:1768−76.
KNOBLACH,S.M.,NIKOLAEVA,M.,HUANG,X.,FAN,L.,KRAJEWSKI,S.,REED,J.C.,and FADEN,A.I.(2002).Multiple caspases are activated after traumatic brain injury:evidence for involvement in functional outcome.J.Neurotrauma 19,1155−1170.
Kosik,K.S.,and Finch,E.A.(1987).MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites:an immunocytochemical study of cultured rat cerebrum.J.Neurosci.7,3142−3153.
KOVESDI E,LUCKL J,BUKOVICS P,FARKAS O,PAL J,CZEITER E,SZELLAR D,DOCZI T,KOMOLY S,BUKI A.(2010). Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics.Acta Neurochir(Wien).152(1):1−17.
KRISHNAMURTHY,S.,and SNEIGE,N.(2002).Molecular and biologic markers of premalignant lesions of human breast.Adv.Anat.Pathol.9,185−197.
LITERSKY,J.M.,SCOTT,C.W.,and JOHNSON,G.V.(1993).Phosphorylation,calpain proteolysis and tubulin binding of recombinant human tau isoforms.Brain Res.604,32−40.
MCCRACKEN,E.,HUNTER,A.J.,PATEL,S.,GRAHAM,D.I.,and DEWAR,D.(1999).Calpain activation and cytoskeletal protein breakdown in the corpus callosum of head−injured patients.J Neurotrauma 16,749−761.
MCINTOSH,T.K.,SMITH,D.H.,MEANEY,D.F.,KOTAPKA,M.J.,GENNARELLI,T.A.,and GRAHAM,D.I.(1996).Neuropathological sequelae of traumatic brain injury:relationship to neurochemical and biomechanical mechanisms.Lab.Invest.74,315−341.
MCKEE AC, CANTU RC, NOWINSKI CJ, HEDLEY−WHYTE ET, GAVETT BE, BUDSON AE, SANTINI VE, LEE HS, KUBILUS CA, STERN RA.(2009).Chronic traumatic encephalopathy in athletes:progressive tauopathy after repetitive head injury.J Neuropathol Exp Neurol. 68(7):709−35.
MEDANA,I.M.,and ESIRI,M.M.(2003).Axonal damage:a key predictor of outcome in human CNS diseases.Brain.126,515−530.
NATH,R.,MCGINNIS,K.J.,NADIMPALLI,R.,STAFFORD,D.,and WANG,K.K.W.(1996).Effects of ICE−like proteases and calpain inhibitors on neuronal apoptosis.NeuroReport.8,249−255.
NATH,R.,PROBERT,A.,JR.,MCGINNIS,K.M.,WANG,K.K.W.(1998)Evidence for Activation of Caspase−3−like Protease in Excitotoxins−and Hypoxia/hypoglycemia−Injured Neurons. J.Neurochem.71, 186−195.
Newcomb JK,Kampfl A,Posmantur RM,Zhao X,Pike BR,Liu SJ,Clifton GL,and Hayes RL.(1997)Immunohistochemical study of calpain−mediated breakdown products to alpha−spectrin following controlled cortical impact injury in the rat.J.Neurotrauma.14,369−383.
NG,H.K.,MAHALIYANA,R.D.,and POON,W.S.(1994).The pathological spectrum of diffuse axonal injury in blunt head trauma:assessment with axon and myelin strains.Clin.Neurol.Neurosurg.96,24−31.
PARK SY,FERREIRA A.(2005)The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta−amyloid−induced neurodegeneration.J Neurosci.25,5365−5375.
PETTUS,E.H.,CHRISTMAN,C.W.,GIEBEL,M.L.,and POVLISHOCK,J.T.(1994).Traumatically induced altered membrane permeability:its relationship to traumatically induced reactive axonal change.J.Neurotrauma.11,507−522.
PIKE,B.R.,ZHAO,X.,NEWCOMB,J.K.,WANG,K.K.W.,POSMANTUR,R.M.,and HAYES,R.L.(1998b).Temporal relationships between de novo protein synthesis,calpain and caspase 3−like protease activation,and DNA fragmentation during apoptosis in septo−hippocampal cultures.J.Neurosci.Res.52,505−520.
PIKE,B.R.,ZHAO,X.,NEWCOMB,J.K.,POSMANTUR,R.M.,WANG,K.K.W.,and HAYES,R.L.(1998).Regional calpain and caspase−3 proteolysis of alpha−spectrin after traumatic brain injury.NeuroReport.9,2437−2442.
PIKE,B.R.,FLINT,J.,DAVE,J.R.,LU,X.C.,WANG,K.K.,TORTELLA,F.C.,and HAYES,R.L.(2004).Accumulation of calpain and caspase−3 proteolytic fragments of brain−derived alphaII−spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats.J Cereb Blood Flow Metab.24,98−106.
POSMANTUR,R.,KAMPFL,A.,SIMAN,R.,LIU,J.,ZHAO,X.,CLIFTON,G.L.,and HAYES R.L.(1997).A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat.Neuroscience.77,875−88.
RAO MV,MOHAN PS,PETERHOFF CM,YANG DS,SCHMIDT SD,STAVRIDES PH,CAMPBELL J,CHEN Y,JIANG Y,PASKEVICH PA,CATALDO AM,HAROUTUNIAN V,NIXON RA.(2008).Marked calpastatin(CAST)depletion in Alzheimer’s disease accelerates cytoskeleton disruption and neurodegeneration:neuroprotection by CAST overexpression.J Neurosci.28(47):12241−54.
RISSMAN RA,POON WW,BLURTON−JONES M,ODDO S, TORP R,VITEK MP,LAFERLA FM,ROHN TT,COTMAN CW.(2004)Caspase−cleavage of tau is an early event in Alzheimer disease tangle pathology.J Clin Invest.114(1),121−30.
ROHN,T.T.,RISSMAN,R.A.,HEAD,E.,and COTMAN,C.W.(2002).Caspase Activation in the Alzheimer’s Disease Brain:Tortuous and Torturous.Drug News Perspect.15,549−557.
SAATMAN,K.E.,BOZYCZKO−COYNE,D.,MARCY,V.,SIMAN,R.,and MCINTOSH,T.K.(1996).Prolonged calpain−mediated spectrin breakdown occurs regionally following experimental brain injury in the rat.J.Neuropathol.Exp.Neurol.55,850−860.
SAATMAN,K.E.,MURAI,H.,BARTUS,R.T.,SMITH,D.H.,HAYWARD,N.J.,PERRI,B.R.,and MCINTOSH T.K.(1996).Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat.Proc.Natl Acad.Sci.USA 93,3428−3433.
SAATMAN,K.E,ZHANG,C.,BARTUS,R.T.,and MCINTOSH,T.K.(2000).Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis,cortical lesion,or apoptosis.J.Cereb.Blood Flow Metab.20,66−73.
SHIMOHAMA S,TANINO H,FUJIMOTO S.(1999)Changes in caspase expression in Alzheimer’s disease:comparison with development and aging.Biochem Biophys Res Commun.256,381−384.
SIMAN R,MCINTOSH TK,SOLTESZ KM,CHEN Z,NEUMAR RW,ROBERTS VL.(2004)Proteins released from degenerating neurons are surrogate markers for acute brain damage.Neurobiol Dis.16(2),311−20.
SINJOANU RC,KLEINSCHMIDT S,BITNER RS,BRIONI JD,MOELLER A,FERREIRA A.(2008).The novel calpain inhibitor A−705253 potently inhibits oligomeric beta−amyloid−induced dynamin 1 and tau cleavage in hippocampal neurons.Neurochem Int.53(3−4):79−88.
URYU K,CHEN XH,MARTINEZ D,BROWNE KD,JOHNSON VE,GRAHAM DI,LEE VM,TROJANOWSKI JQ,SMITH DH.(2007)Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol.208,185−92.
VAN DEN HEUVEL C,THORNTON E,VINK R.(2007)Traumatic brain injury and Alzheimer’s disease:a review.Prog Brain Res.161:303−16.
WANG,K.K.W.(2000).Calpain and caspase:can you tell the difference? Trends Neurosci.23,20−26.
WARREN,M.W.,KOBEISSY,F.H., HAYES,R.L.,GOLD,M.S.,WANG,K.K.W.(2005)Concurrent calpain and caspase−3 mediated proteolysis of αII−spectrin and tau in rat brain after methamphetamine exposure:A similar profile to traumatic brain injury.Life Sciences 78:301−309.
WARREN,MW. ZHENG,W.R.,KOBEISSY,F.,LIU,M.C.,,HAYES,R.L.,GOLD,MARK,M.C.LIU,AND WANG,K.K.W.(2006)Calpain and caspase mediated proteolysis of αII−spectrin and tau in rat cerebrocortical neuron cultures after ecstasy(MDMA)or methamphetamine exposure Int.J.Neuropsypharm.9,1−11.
YANG L.S.,and KSIEZAK−REDING,H.(1995).Calpain−induced proteolysis of normal human tau and tau associated with paired helical filaments. J.Biochem.233,9−17.
YEN,S.,EASSON,C.,NACHARAJU,P.,HUTTON,M.,and YEN,S.H.(1999).FTDP−17 tau mutations decrease the susceptibility of tau to calpain I digestion.FEBS Lett.461,91−95.
YOSHIYAMA Y,URYU K,HIGUCHI M,LONGHI L,HOOVER R,FUJIMOTO S,MCINTOSH T,LEE VM,TROJANOWSKI JQ.(2005)Enhanced neurofibrillary tangle formation,cerebral atrophy,and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model.J Neurotrauma.22,134−1141.
ZEMLAN,F.P.,JAUCH,E.C.,MULCHAHEY,J.J.,GABBITA,S.P.,and ROSENBERG,W.S.Speciale SG,and Zuccarello M.(2002).C−tau biomarker of neuronal damage in severe brain injured patients:association with elevated intracranial pressure and clinical outcome.Brain Res.23,131−139.
ZEMLAN,F.P.,MULCHAHEY,J.J.,and GUDELSKY,G.A.(2003).Quantification and localization of kainic acid−induced neurotoxicity employing a new biomarker of cell death:cleaved microtubule−associated protein−tau(C−tau).Neuroscience 121,399−409.
ZHANG JY,PENG C,SHI H,WANG S,WANG Q,WANG JZ.(2009)Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain.J Alzheimers Dis.16,39−47.
ZHANG Z,LARNER S,LIU MC,ZHENG W,HAYES RL,WANG KKW.(2009)Multiple αII−spectrin Breakdown Products Distinguish Calpain and Caspase Dominated Necrotic and Apoptotic Cell Death Pathways.Apoptosis, 14,1289−1298.
Claims (1)
- 神経学的状態を検出するための工程であって、
生物試料中の損傷後に変化する1つ以上のニューロン特異的バイオマーカーを測定することと、
前記生物試料中の1つ以上の前記バイオマーカーの比率に基づいて神経学的状態を検出することと
を含む工程。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24212309P | 2009-09-14 | 2009-09-14 | |
US61/242,123 | 2009-09-14 | ||
US35450410P | 2010-06-14 | 2010-06-14 | |
US61/354,504 | 2010-06-14 | ||
US35577910P | 2010-06-17 | 2010-06-17 | |
US61/355,779 | 2010-06-17 | ||
US38015810P | 2010-09-03 | 2010-09-03 | |
US61/380,158 | 2010-09-03 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015253708A Division JP2016105097A (ja) | 2009-09-14 | 2015-12-25 | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017181518A true JP2017181518A (ja) | 2017-10-05 |
JP2017181518A5 JP2017181518A5 (ja) | 2017-11-30 |
JP6469760B2 JP6469760B2 (ja) | 2019-02-13 |
Family
ID=43733138
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012528991A Active JP5909447B2 (ja) | 2009-09-14 | 2010-09-14 | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
JP2015253708A Pending JP2016105097A (ja) | 2009-09-14 | 2015-12-25 | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
JP2017111070A Active JP6469760B2 (ja) | 2009-09-14 | 2017-06-05 | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012528991A Active JP5909447B2 (ja) | 2009-09-14 | 2010-09-14 | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
JP2015253708A Pending JP2016105097A (ja) | 2009-09-14 | 2015-12-25 | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
Country Status (8)
Country | Link |
---|---|
US (3) | US20130022982A1 (ja) |
EP (1) | EP2478360B1 (ja) |
JP (3) | JP5909447B2 (ja) |
AU (2) | AU2010291933B2 (ja) |
CA (1) | CA2774173A1 (ja) |
ES (1) | ES2687469T3 (ja) |
HU (1) | HUE040281T2 (ja) |
WO (1) | WO2011032155A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8492107B2 (en) | 2004-04-15 | 2013-07-23 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
JP5781436B2 (ja) | 2008-08-11 | 2015-09-24 | バンヤン・バイオマーカーズ・インコーポレーテッド | 神経学的状態のバイオマーカー検出方法およびアッセイ |
AU2010262952B2 (en) * | 2009-06-19 | 2016-01-07 | Banyan Biomarkers, Inc. | Biomarker assay of neurological condition |
US20170315136A9 (en) * | 2009-06-19 | 2017-11-02 | Banyan Biomarkers, Inc. | Biomarker assay of neurological condition |
EP2478360B1 (en) | 2009-09-14 | 2018-06-27 | Banyan Biomarkers, Inc. | Autoantibody markers for diagnosis of traumatic brain injury |
WO2012045324A1 (en) * | 2010-10-07 | 2012-04-12 | Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh | Method for detecting a parkinson's disease and test system |
WO2012051519A2 (en) | 2010-10-14 | 2012-04-19 | The Johns Hopkins University | Biomarkers of brain injury |
DE102011011280A1 (de) * | 2011-02-15 | 2012-08-16 | Euroimmun Medizinische Labordiagnostika Ag | Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikörpern |
WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
US20140206777A1 (en) * | 2011-08-16 | 2014-07-24 | Rosetta Genomics Ltd. | Methods and compositions for diagnosis of alzheimer's disease |
WO2013138509A1 (en) * | 2012-03-13 | 2013-09-19 | The Johns Hopkins University | Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration |
WO2013173596A1 (en) * | 2012-05-16 | 2013-11-21 | Trustees Of Boston University | Chronic traumatic encephalopathy in blast-exposed individuals |
SG11201408626YA (en) * | 2012-07-03 | 2015-03-30 | Univ Washington | Antibodies to tau |
US20140073524A1 (en) * | 2012-09-07 | 2014-03-13 | Institute For Systems Biology | Markers and methods for detecting posttraumatic stress disorder (ptsd) |
US9856532B2 (en) * | 2012-09-07 | 2018-01-02 | Institute For Systems Biology | Markers and methods for detecting posttraumatic stress disorder (PTSD) |
EP3022322A4 (en) | 2013-07-17 | 2017-05-17 | The Johns Hopkins University | A multi-protein biomarker assay for brain injury detection and outcome |
GB201319761D0 (en) * | 2013-11-08 | 2013-12-25 | Nordic Bioscience As | Biomarkers of disease progression |
CN103656685B (zh) * | 2014-01-10 | 2016-01-13 | 厦门大学 | microRNA-219在制备抗癫痫药物中的应用 |
WO2015134551A1 (en) * | 2014-03-03 | 2015-09-11 | Banyan Biomarkers, Inc. | Micro rna markers for diagnosis of a neurological condition |
US9605315B2 (en) * | 2014-03-26 | 2017-03-28 | The University Of Montana | Detection of traumatic brain injury |
CN106461645A (zh) * | 2014-04-07 | 2017-02-22 | 铁马诊断公司 | 外伤性脑损伤和神经退行性生物标记物、方法和系统 |
WO2015157390A1 (en) * | 2014-04-08 | 2015-10-15 | University Of Florida Research Foundation, Incorporated | Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system |
WO2015160391A1 (en) * | 2014-04-15 | 2015-10-22 | The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research | Diagnosis and treatment of tauopathy and chronic traumatic encephalopathy |
WO2015196191A1 (en) * | 2014-06-20 | 2015-12-23 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Microrna biomarkers for traumatic brain injury and methods of use thereof |
CA2962593A1 (en) * | 2014-09-26 | 2016-03-31 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Microrna biomarkers for posttraumatic stress disorder and methods of use thereof |
CN107003317B (zh) * | 2014-10-06 | 2019-04-19 | 日内瓦大学 | 生物标记及其在脑损伤中的应用 |
WO2016125148A1 (en) * | 2015-02-05 | 2016-08-11 | Immunarray Ltd. | Methods and compositions for diagnosing brain injury or neurodegeneration |
WO2016205730A1 (en) * | 2015-06-18 | 2016-12-22 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Citrullinated proteins and their breakdown products as tbi biomarkers |
JP2018522558A (ja) * | 2015-07-29 | 2018-08-16 | ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 外傷性脳損傷のためのマイクロrnaバイオマーカー、及びその使用方法 |
EP3347493B1 (en) * | 2015-09-08 | 2022-03-30 | The Translational Genomics Research Institute | Biomarkers and methods of diagnosing mild traumatic brain injuries |
CA3042630A1 (en) * | 2015-11-18 | 2017-05-26 | Dignity Health | Methods of diagnosing epilepsy |
GB201603967D0 (en) * | 2016-03-08 | 2016-04-20 | Univ Birmingham | Biomarkers of traumatic brain injury |
WO2017187696A1 (ja) * | 2016-04-28 | 2017-11-02 | 一般財団法人生産技術研究奨励会 | 神経細胞を培養する装置、神経細胞を培養する方法、培養された神経細胞、軸索束内のプロテインを解析及び同定する方法並びに神経細胞の使用方法 |
JP2019521319A (ja) * | 2016-05-06 | 2019-07-25 | デューク ユニバーシティ | 神経系疾患または損傷を診断および治療するための方法並びにキット |
US11402379B2 (en) | 2016-09-09 | 2022-08-02 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating autoimmune GFAP astrocytopathy |
IT201600093825A1 (it) * | 2016-09-19 | 2018-03-19 | Fondazione St Italiano Tecnologia | Composizione farmaceutica di miRNA e suoi usi terapeutici. |
WO2018081649A1 (en) | 2016-10-28 | 2018-05-03 | Banyan Biomarkers, Inc. | Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods |
WO2018096049A1 (en) * | 2016-11-23 | 2018-05-31 | Randox Laboratories Ltd | Gfap derivatives for stroke diagnostics |
EP3580355A4 (en) * | 2017-02-07 | 2020-12-16 | Bioregency, Inc. | S100BETA AND ITS ISOFORMS FOR THE DETECTION OF NEUROLOGICAL AFFECTIONS |
AU2018221049A1 (en) | 2017-02-17 | 2019-09-19 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
CA3052513A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
WO2018190365A1 (ja) * | 2017-04-12 | 2018-10-18 | 国立大学法人九州大学 | 神経障害性疼痛マーカー及びその使用 |
CN110546513A (zh) | 2017-04-15 | 2019-12-06 | 雅培实验室 | 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法 |
CA3053410A1 (en) | 2017-04-28 | 2018-11-01 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
JP7416625B2 (ja) | 2017-05-25 | 2024-01-17 | アボット・ラボラトリーズ | 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法 |
US10849548B2 (en) | 2017-05-30 | 2020-12-01 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers |
EP3631448A4 (en) * | 2017-06-02 | 2021-03-03 | The Johns Hopkins University | DETECTION OF PAR IN THE CSF OF PATIENTS WITH PARKINSON'S DISEASE |
CA3068041C (en) | 2017-07-03 | 2024-06-25 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
JP7550643B2 (ja) | 2017-10-25 | 2024-09-13 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | リン酸化タウペプチドの組成物およびその使用 |
JP6942036B2 (ja) * | 2017-11-30 | 2021-09-29 | 藤倉化成株式会社 | 脳梗塞の発症リスクを高感度に検出する体液抗体バイオマーカー |
WO2019113525A2 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
JP7379165B2 (ja) | 2017-12-09 | 2023-11-14 | アボット・ラボラトリーズ | Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法 |
CN111699391A (zh) | 2017-12-29 | 2020-09-22 | 雅培实验室 | 用于诊断和评估创伤性脑损伤的新型生物标志物和方法 |
KR102026675B1 (ko) * | 2018-02-12 | 2019-09-30 | 강원대학교산학협력단 | miR-135a-5p 및 p62에 의한 알레르기 반응 조절 메커니즘 및 이의 이용 |
JP6499342B2 (ja) * | 2018-03-19 | 2019-04-10 | 隆樹 日和佐 | 脳梗塞の診断マーカー |
WO2019207159A1 (en) * | 2018-04-27 | 2019-10-31 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
EP3827099A4 (en) * | 2018-07-25 | 2022-07-20 | sRNAlytics, Inc. | SMALL RNA PREDICTORS FOR ALZHEIMER'S DISEASE |
CN110824156B (zh) * | 2018-08-14 | 2023-08-11 | 欧蒙医学诊断(中国)有限公司 | 神经自身免疫疾病的诊断 |
WO2020081641A1 (en) * | 2018-10-17 | 2020-04-23 | Ochsner Health System | Plasma and cerebrospinal fluid mirna biomarkers in intracerebral and subarachnoid hemorrhage |
CN109266739A (zh) * | 2018-11-29 | 2019-01-25 | 成都仕康美生物科技有限公司 | 一种检测脑损伤的miRNA标志物、试剂盒、应用 |
WO2020113271A1 (en) * | 2018-12-04 | 2020-06-11 | La Trobe University | Methods of diagnosing a disease state |
JP2022520427A (ja) * | 2019-02-14 | 2022-03-30 | マーカー ダイアグノスティクス ユーケイ リミテッド | 脳損傷の唾液バイオマーカー |
GB201909393D0 (en) * | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
CN110551809A (zh) * | 2019-08-21 | 2019-12-10 | 昆明医科大学第一附属医院 | miR-124在脊髓损伤修复中的用途 |
US11644463B2 (en) * | 2019-08-30 | 2023-05-09 | Euroimmun Medizinische Labordiagnostika Ag | Detection of an autoantibody |
US20230250480A1 (en) * | 2020-07-09 | 2023-08-10 | University Of Florida Research Foundation, Incorporated | Biofluid-based protein and mirna biomarkers for neonatal hypoxic-ischemic encephalopathy |
EP4200331A4 (en) * | 2020-08-24 | 2024-09-18 | Marabio Systems Inc | METHODS TO REDUCE AUTOANTIBODIES IN THE MOTHER |
CN113238045B (zh) * | 2021-04-27 | 2021-12-28 | 南方医科大学南方医院 | Crmp2及抗crmp2抗体的应用 |
TWI853766B (zh) * | 2022-12-22 | 2024-08-21 | 國立臺灣大學 | 用於心跳停止病患頭部電腦斷層之灰白質比率自動計算方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492812A (en) * | 1991-08-01 | 1996-02-20 | Provost, Fellows And Scholars Of Trinity College | Diagnostic method for Alzheimer's disease by screening for tau-peptides in the blood of a patient |
JP2003503314A (ja) * | 1999-06-16 | 2003-01-28 | モレキュウラー ジェリアトリクス コーポレイション | アルツハイマー病の精製抗原およびそれを獲得および使用する方法 |
WO2007094395A1 (ja) * | 2006-02-15 | 2007-08-23 | Mie University | 診断用組換えプロテオリポソームの作製法 |
JP2007535318A (ja) * | 2004-04-15 | 2007-12-06 | バンヤン バイオマーカーズ | 癌、器官傷害、および筋肉リハビリテーション/運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
DE69133513T2 (de) | 1990-06-11 | 2006-09-21 | Gilead Sciences, Inc., Foster City | Verfahren zur Verwendung von Nukleinsäureliganden |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5731410A (en) | 1994-11-28 | 1998-03-24 | University Of Utah Research Foundation | Peptide for blocking autoantibody-evoked activation of glutamate receptor type 3 (GLUR3) |
CA2340433A1 (en) | 1998-09-08 | 2000-03-16 | Innogenetics N.V. | Tau as a marker for early cns damage |
US6589746B1 (en) * | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
US20030199000A1 (en) | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US20040203083A1 (en) | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20020172676A1 (en) * | 2001-05-16 | 2002-11-21 | George Jackowski | Method of treatment of alzheimer's disease and device therefor |
US7144708B2 (en) | 2001-06-25 | 2006-12-05 | The Cleveland Clinic Foundation | Markers of blood barrier disruption and methods of using same |
CA2457775A1 (en) | 2001-08-20 | 2003-02-27 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
WO2003032894A2 (en) | 2001-10-12 | 2003-04-24 | Pfizer Products Inc. | Method of monitoring neuroprotective treatment |
EP1551450A4 (en) | 2002-06-12 | 2005-11-23 | Cleveland Clinic Foundation | MARKER FOR THE PERMEABILITY OF THE BLOOD BARRIER AND METHOD FOR THEIR USE |
CA2498614C (en) | 2002-09-11 | 2013-04-16 | University Of Florida | Analyzing nerve cell damage |
EP1587955A4 (en) | 2002-12-24 | 2007-03-14 | Biosite Inc | DIFFERENTIAL DIAGNOSTIC MARKERS AND METHODS OF USE |
EP1664795B1 (en) | 2003-09-20 | 2017-11-08 | Electrophoretics Limited | Diagnostic method for brain damage-related disorders |
EP1519194A1 (en) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
US20140303041A1 (en) | 2004-04-15 | 2014-10-09 | University Of Florida Research Foundation Inc. | In vitro diagnostic devices for nervous system injury and other neural disorders |
CA2578670C (en) | 2004-04-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
US8492107B2 (en) | 2004-04-15 | 2013-07-23 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
GB2428240A (en) | 2005-07-14 | 2007-01-24 | Univ Gen Ve | Diagnostic method for brain damage-related disorders |
EP1949103A2 (en) | 2005-10-20 | 2008-07-30 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
WO2007136617A2 (en) * | 2006-05-18 | 2007-11-29 | Walter Reed Army Institute Of Research (Wrair) | Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury |
EP2024395A4 (en) | 2006-05-26 | 2009-07-01 | Biosite Inc | USE OF NATRIURETIC PEPTIDES AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES |
AU2009212463A1 (en) * | 2008-02-04 | 2009-08-13 | Banyan Biomarkers, Inc. | Process to diagnose or treat brain injury |
EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
JP5781436B2 (ja) | 2008-08-11 | 2015-09-24 | バンヤン・バイオマーカーズ・インコーポレーテッド | 神経学的状態のバイオマーカー検出方法およびアッセイ |
US20140342381A1 (en) | 2008-08-11 | 2014-11-20 | Banyan Biomarkers, Inc. | Devices and methods for biomarker detection process and assay of neurological condition |
WO2010059242A2 (en) | 2008-11-21 | 2010-05-27 | The Johns Hopkins University | Neurodegenerative disease diagnostic compositions and methods of use |
AU2010262952B2 (en) | 2009-06-19 | 2016-01-07 | Banyan Biomarkers, Inc. | Biomarker assay of neurological condition |
US20170315136A9 (en) | 2009-06-19 | 2017-11-02 | Banyan Biomarkers, Inc. | Biomarker assay of neurological condition |
US20120202231A1 (en) | 2009-07-18 | 2012-08-09 | Kevin Ka-Wang Wang | Synergistic biomarker assay of neurological condition using s-100b |
EP2478360B1 (en) | 2009-09-14 | 2018-06-27 | Banyan Biomarkers, Inc. | Autoantibody markers for diagnosis of traumatic brain injury |
WO2011123844A2 (en) * | 2010-04-01 | 2011-10-06 | Banyan Biomarkers, Inc. | Markers and assays for detection of neurotoxicity |
WO2011160096A2 (en) | 2010-06-17 | 2011-12-22 | Banyan Biomarkers, Inc. | Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition |
EP2756313A4 (en) | 2011-09-14 | 2015-04-22 | Jackson H M Found Military Med | METHOD AND KITS FOR DETECTING AND MONITORING DIAGNOSTIC BIOMARKERS FOR POSTTRAUMATIC LOAD DISORDER (PTSD) AND DISTINCTION BETWEEN SUICID AND NON-SUCCIDANT FORMS OF DISORDER |
US20140024053A1 (en) | 2012-07-20 | 2014-01-23 | Banyan Biomarkers, Inc. | Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury |
US20140275294A1 (en) | 2013-03-15 | 2014-09-18 | Banyan Biomarkers, Inc. | Devices and methods for biomarker detection process and assay of liver injury |
US20150141528A1 (en) | 2013-05-31 | 2015-05-21 | Banyan Biomarkers, Inc. | Neural specific s100b for biomarker assays and devices for detection of a neurological condition |
-
2010
- 2010-09-14 EP EP10816275.1A patent/EP2478360B1/en not_active Revoked
- 2010-09-14 CA CA2774173A patent/CA2774173A1/en not_active Abandoned
- 2010-09-14 HU HUE10816275A patent/HUE040281T2/hu unknown
- 2010-09-14 ES ES10816275T patent/ES2687469T3/es active Active
- 2010-09-14 AU AU2010291933A patent/AU2010291933B2/en not_active Expired - Fee Related
- 2010-09-14 WO PCT/US2010/048789 patent/WO2011032155A2/en active Application Filing
- 2010-09-14 US US13/395,931 patent/US20130022982A1/en not_active Abandoned
- 2010-09-14 JP JP2012528991A patent/JP5909447B2/ja active Active
-
2015
- 2015-12-25 JP JP2015253708A patent/JP2016105097A/ja active Pending
-
2016
- 2016-12-07 AU AU2016269481A patent/AU2016269481B2/en not_active Ceased
- 2016-12-27 US US15/391,755 patent/US10041959B2/en active Active
-
2017
- 2017-06-05 JP JP2017111070A patent/JP6469760B2/ja active Active
-
2018
- 2018-08-01 US US16/052,512 patent/US20190064188A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492812A (en) * | 1991-08-01 | 1996-02-20 | Provost, Fellows And Scholars Of Trinity College | Diagnostic method for Alzheimer's disease by screening for tau-peptides in the blood of a patient |
JP2003503314A (ja) * | 1999-06-16 | 2003-01-28 | モレキュウラー ジェリアトリクス コーポレイション | アルツハイマー病の精製抗原およびそれを獲得および使用する方法 |
JP2007535318A (ja) * | 2004-04-15 | 2007-12-06 | バンヤン バイオマーカーズ | 癌、器官傷害、および筋肉リハビリテーション/運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー |
WO2007094395A1 (ja) * | 2006-02-15 | 2007-08-23 | Mie University | 診断用組換えプロテオリポソームの作製法 |
Non-Patent Citations (1)
Title |
---|
WARREN, MW ET AL., LIFE SCIENCE, vol. 78(3), JPN6018013231, 5 December 2005 (2005-12-05), pages 301 - 309, ISSN: 0003777231 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
WO2022124564A1 (ko) * | 2020-12-10 | 2022-06-16 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
Also Published As
Publication number | Publication date |
---|---|
WO2011032155A3 (en) | 2011-10-06 |
ES2687469T3 (es) | 2018-10-25 |
HUE040281T2 (hu) | 2019-03-28 |
WO2011032155A2 (en) | 2011-03-17 |
AU2010291933A1 (en) | 2012-05-10 |
JP6469760B2 (ja) | 2019-02-13 |
CA2774173A1 (en) | 2011-03-17 |
JP2013504331A (ja) | 2013-02-07 |
AU2010291933B2 (en) | 2016-09-08 |
JP5909447B2 (ja) | 2016-04-26 |
US20130022982A1 (en) | 2013-01-24 |
EP2478360B1 (en) | 2018-06-27 |
JP2016105097A (ja) | 2016-06-09 |
US10041959B2 (en) | 2018-08-07 |
US20190064188A1 (en) | 2019-02-28 |
EP2478360A4 (en) | 2013-04-03 |
US20170242041A1 (en) | 2017-08-24 |
AU2016269481A1 (en) | 2016-12-22 |
AU2016269481B2 (en) | 2018-08-30 |
EP2478360A2 (en) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6469760B2 (ja) | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー | |
EP3336551B1 (en) | Biomarker detection process and assay of neurological condition | |
AU2011235892B2 (en) | Markers and assays for detection of neurotoxicity | |
AU2010262952B2 (en) | Biomarker assay of neurological condition | |
US20170315136A9 (en) | Biomarker assay of neurological condition | |
EP3115785A2 (en) | Process to diagnose or treat brain injury | |
WANG et al. | Patent 2774173 Summary | |
JP6338872B2 (ja) | 視神経障害発症リスクの判定方法 | |
US7879568B2 (en) | Method for the diagnosis and prognosis of demyelinating diseases | |
Garmy et al. | Cellular isoform of the prion protein PrPc in human intestinal cell lines: genetic polymorphism at codon 129, mRNA quantification and protein detection in lipid rafts | |
Kovacs | First Scientific Session | |
AU2015203660A1 (en) | Process to diagnose or treat brain injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171019 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180713 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6469760 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |